Sepetaprost

DB12043InvestigationalSmall molecule

Sepetaprost has been used in trials studying the treatment of Open Angle-glaucoma, Ocular Hypertension, and Mild Open Angle-glaucoma (OAG).

Mechanism: Pharmacologically active on Prostaglandin F2-alpha receptor and Prostaglandin E2 receptor EP3 subtype
Curator reviewed
Formula / weight: C₂₆H₃₆F₂O₆ · 482.565 g/mol (avg)
Code names: ONO-9054

Resolves to

Compound

Structure

InChIKeyBKVUSNOUTQMSBE-XCMGCKIWSA-NSMILESCC(C)OC(=O)CCC[C@H]1CC[C@H]2[C@H](C[C@@H](O)[C@@H]2\C=C\[C@@H](O)COC2=CC(F)=CC=C2F)OC1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sepetaprost, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.